Clinical Trials

Find a Trial

Trial Summary

Protocol No.IUCRO-0419
Principal InvestigatorFarag, Sherif
PhasePhase II
Age GroupAdult
TitleA Phase II Trial of Prostaglandin E2 Inhibition, using Meloxicam, plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma and Non-Hodgkin?s Lymphoma
DescriptionThis is an open label Simon optimal two-stage Phase II trial of fixed doses of oral The trial is an open label Simon optimal two-stage Phase II trial of fixed doses of oral meloxicam and subcutaneous filgrastim to assess the safety and efficacy in mobilizing autologous peripheral blood stem cells (PBSC) from multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) patients planning to undergo high-dose chemotherapy with stem cell support. Clinical data regarding the cellular composition and function of the graft mobilized by this combination will be obtained.
Key EligibilityTo be eligible for this trial subjects must
  • Have a previously documented histologic diagnosis of multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL)
  • Have disease in first or second partial response or better
  • Be between 18 and 75 years of age at study entry

    For a full list of eligibility criteria and additional study information visit
Applicable Disease SitesLymphoma, Non-Hodgkin's (Adult)
Multiple Myeloma /Plasma Cell Neoplasm
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactPhone: (317) 278-5632